Drug Trial Radar · NCT05265650
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 13, 2022
Primary completion
Mar 2024
Study completion Jun 2024
Sponsor
- Lead sponsor
- Clinica Universidad de Navarra, Universidad de NavarraAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Highlight Therapeutics
- First posted
- Mar 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.
Conditions
- Non-Small Cell Lung Cancer Metastatic
Interventions
BO-112 in combination with ablative radiotherapy (SABR) and nivolumabDrug
Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
Tissue BiopsiesProcedure
Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse events and Serious Adverse EventsTime frame: Throughout study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clínica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.